Johnson & Johnson’s subcutaneous Tremfya holds potential to set new standard in Crohn’s disease treatment
- Posted on October 21, 2024
- By Financial Express
- 3 Views
Johnson & Johnson’s subcutaneous Tremfya holds potential to set new standard in Crohn’s disease treatment
According to GlobalData’s Sales and Forecast database, total sales for Tremfya are expected to reach $7.8 billion globally by 2029.
